JPWO2020247576A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020247576A5 JPWO2020247576A5 JP2021572295A JP2021572295A JPWO2020247576A5 JP WO2020247576 A5 JPWO2020247576 A5 JP WO2020247576A5 JP 2021572295 A JP2021572295 A JP 2021572295A JP 2021572295 A JP2021572295 A JP 2021572295A JP WO2020247576 A5 JPWO2020247576 A5 JP WO2020247576A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- therapeutic agent
- ratio
- subject
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
次に、開発した治療薬の抗転移活性を末期の肺転移において調べた。図8Aに示されるように、腫瘍細胞の静脈内注射後、マウスに4回の用量の治療薬の投与を1日おきに受けさせ、最初の用量は移植の1週間後(7日目に)投与した。個々のマウスの生物発光画像(図8B)および肺転移の増殖曲線(図8C)によれば、薬物ナノ粒子単独の使用では、肺転移の進行の有意な抑止はもたらされなかった。しかしながら、赤血球上で自己集合している薬物ナノ粒子(ELeCt)では肺転移の進行を遅らせることができたが、早期転移モデルの場合ほど著しくはなかった。具体的には、赤血球上で自己集合している薬物ナノ粒子での処置を受けた7匹のマウスのうち2匹は、腫瘍移植後16日目まで完全に肺転移なしのままであった。図8Dに示す全肺転移量データにより、ナノ粒子単独の使用より良好な便乗薬物ナノ粒子の有効性が確認された。特に、腫瘍移植後16日目、便乗薬物ナノ粒子は、転移部の増殖の抑止に関して2.4倍良好な有効性を示した。16日目、肺を摘出し、肺上の表面転移結節を計数した。図8Eに示す表面結節データは、生物発光を用いて評価した生物発光転移量データと整合する。表面結節の低減における2.3倍良好な有効性は、薬物ナノ粒子を赤血球に自己集合させることによって得られた。マウスの肺のH&E解析によってこの結果を確認した(図10)。また、図8Fに示す体重変化データおよび図11に示すH&E解析データにより、いずれの処置も有意な毒性とは関連していないことが示された。動物の生存期間の延長に関する治療薬の有効性を評価するための別個の試験を実施した。図8Gに示されるように、早期転移モデルとは異なり、薬物ナノ粒子単独の使用では、なんら生存度の有益性はもたらされなかった。しかしながら、赤血球上で自己集合している薬物ナノ粒子を用いた処置(ELeCt)では、動物の生存度が有意に改善され、生存期間の中央値が28.5日間から37日間に延びた。特に、便乗薬物ナノ粒子の投与を受けた8匹のマウスのうち1匹は少なくとも48日間、生存し続けた。
Next, the anti-metastatic activity of the developed therapeutic agent was investigated in end-stage lung metastases. As shown in FIG. 8A, following intravenous injection of tumor cells, mice received four doses of treatment every other day, the first dose being administered one week after implantation (on day 7). dosed. Bioluminescence images of individual mice (FIG. 8B) and lung metastasis growth curves (FIG. 8C) showed that the use of drug nanoparticles alone did not result in significant arrest of lung metastasis progression. However, drug nanoparticles self-assembling on erythrocytes (ELeCt) were able to slow the progression of lung metastasis, but not as significantly as in the early metastasis model. Specifically, 2 out of 7 mice treated with drug nanoparticles self-assembling on red blood cells remained completely lung metastasis-free up to 16 days after tumor implantation. The total lung metastatic burden data shown in Figure 8D confirmed the efficacy of the opportunistic drug nanoparticles better than the use of nanoparticles alone. Notably, 16 days after tumor implantation, the opportunistic drug nanoparticles showed 2.4 times better efficacy in inhibiting metastasis growth. On day 16, lungs were excised and surface metastatic nodules on lungs were counted. The surface nodule data shown in Figure 8E are consistent with the bioluminescence transfer volume data assessed using bioluminescence. A 2.3-fold better efficacy in reducing surface nodules was obtained by self-assembling drug nanoparticles into red blood cells. H&E analysis of mouse lungs confirmed this result (Fig. 10). Also, the weight change data shown in FIG. 8F and the H&E analysis data shown in FIG. 11 indicated that neither treatment was associated with significant toxicity. A separate study was conducted to assess the effectiveness of therapeutic agents in prolonging animal survival. As shown in Figure 8G , unlike the early metastasis model, the use of drug nanoparticles alone did not confer any viability benefit. However, treatment with drug nanoparticles self-assembling on red blood cells (ELeCt) significantly improved animal survival, extending median survival from 28.5 days to 37 days. Notably, 1 out of 8 mice that received opportunistic drug nanoparticles remained alive for at least 48 days.
EASIによって局所エフェクター細胞の浸潤がもたらされ、これにより転移の進行および生存度の改善有意に抑止された
転移部位でのケモカイン勾配の回復によって誘起されるインサイチュー免疫応答を評価するため、本発明者らは、種々の処置後の肺転移巣内の免疫細胞をプロファイリングするための試験を実施した(図18A)。CXCL10は、特定の類型の免疫細胞、例えばすべて抗腫瘍応答に有利であるTh1 CD4、エフェクターCD8およびNK細胞に対する強力な化学誘引物質である11,36~38。図43Aに示されるように、EASIにより、対照(生理食塩水)と比べて全CD4細胞の1.4倍の増加がもたらされた。さらに、本発明者らにより、EASIによって処置された肺転移巣では生理食塩水群との比較において有意に多い(2.2倍の増加)IFN-γ+Th1 CD4細胞が観察された(図18B~18C)。肺転移巣内の全CD8 T細胞は、種々の処置群間で有意に異ならなかった(図43B)。しかしながら、EASIでは、その他の群と比べてIFN-γ+CD8細胞の浸潤(1.8~2.0倍の増加)およびグランザイムB+CD8細胞の浸潤(1.6~2.2倍の増加)が有意に向上した(図18D~18G)。適応免疫細胞の他に、本発明者らにより、EASIによって、自然免疫細胞(NK細胞)の浸潤が有意に変化することもまた観察された。EASIによって対照群および他の処置群と比べて1.4~1.8倍高いNK細胞浸潤が得られた。上記の免疫細胞プロファイリングデータにより、EASIによって可能となった免疫回復によって肺転移巣内へのエフェクター免疫細胞の浸潤が有意に向上することが明白に示された。具体的には、Th1 CD4細胞は、IFN-γおよびTNF-αなどの1型サイトカインを分泌し、腫瘍の免疫学的制御に有利な炎症促進性環境を維持する39,40。エフェクターCD8細胞およびNK細胞は、がん細胞の直接的な細胞傷害性死滅を推進する主要な寄与因子である41,42。さらに、他の器官での免疫プロファイリング(図44A~44B)により、他の器官、例えば肝臓および脾臓の試験した免疫細胞は、肺のものと比べてEASIによる影響は少ないことが示された。さらに、免疫細胞の浸潤の改善により、肺転移巣内のサイトカインプロフィールが有意に調節された。EASI群における炎症性サイトカインレベルは概ね対照群および他の処置群より高かった(図32)。特に、対照および他の処置と比べて、EASIにより有意に高いIFN-γおよびTNF-αの濃度がもたらされた(図18L,18M)。より興味深いことには、EASI群におけるCXCL10ケモカインの濃度もまた、他の群より顕著に高く、成功裡の免疫回復がさらに確認された。
EASI led to local effector cell infiltration, which significantly inhibited metastatic progression and improved survival. We conducted a study to profile immune cells within lung metastases after various treatments (Fig. 18A). CXCL10 is a potent chemoattractant for certain types of immune cells, such as Th1 CD4, effector CD8 and NK cells, all of which favor anti-tumor responses 11,36-38 . As shown in Figure 43A, EASI resulted in a 1.4-fold increase in total CD4 cells compared to control (saline). Furthermore, we observed significantly more (2.2-fold increase) IFN-γ+ Th1 CD4 cells in EASI-treated pulmonary metastases compared to the saline group (FIGS. 18B- 18C ). . Total CD8 T cells within lung metastases did not differ significantly between the various treatment groups (Fig. 43B). However, EASI significantly improved IFN-γ + CD8 cell infiltration (1.8- to 2.0-fold increase) and Granzyme B + CD8 cell infiltration (1.6- to 2.2-fold increase) compared to other groups (Figures 18D-18G). . Besides adaptive immune cells, we also observed that EASI significantly altered the infiltration of innate immune cells (NK cells). EASI resulted in 1.4- to 1.8-fold higher NK cell infiltration compared to control and other treatment groups. The above immune cell profiling data clearly demonstrated that EASI-enabled immune recovery significantly enhanced the infiltration of effector immune cells into pulmonary metastases. Specifically, Th1 CD4 cells secrete type 1 cytokines such as IFN-γ and TNF-α and maintain a pro-inflammatory environment that favors tumor immunological control 39,40 . Effector CD8 cells and NK cells are major contributors driving the direct cytotoxic killing of cancer cells 41,42 . Furthermore, immune profiling in other organs (FIGS. 44A-44B) showed that tested immune cells in other organs, such as liver and spleen, were less affected by EASI than those in the lung. Moreover, improved immune cell infiltration significantly modulated the cytokine profile within lung metastases. Inflammatory cytokine levels in the EASI group were generally higher than the control and other treatment groups (Figure 32). Notably, EASI resulted in significantly higher levels of IFN-γ and TNF-α compared to controls and other treatments (FIGS. 18L, 18M). More interestingly, the concentration of CXCL10 chemokine in the EASI group was also significantly higher than the other groups, further confirming the successful immune recovery.
Claims (59)
b. 該赤血球の細胞表面上に位置する、PLGAと少なくとも1種の治療剤とを含む粒子
を含む、改変細胞組成物。 a. Red blood cells, and
b. A modified cell composition comprising particles comprising PLGA and at least one therapeutic agent located on the cell surface of said red blood cells.
化学療法剤、抗原、ステロイド、免疫抑制剤、免疫賦活剤、ウイルス、小分子、ペプチド、核酸、およびケモカイン
から選択される、請求項1~18のいずれか一項記載の組成物。 The at least one therapeutic agent is
19. The composition of any one of claims 1-18, wherein the composition is selected from chemotherapeutic agents, antigens, steroids, immunosuppressants, immunostimulants, viruses, small molecules, peptides, nucleic acids, and chemokines.
ドキソルビシン、カンプトテシン、パクリタキセル、ドセタキセル、5-フルオロウラシル、ゲムシタビン、メトトレキサート、またはそれらの組み合わせ
からなる群より選択される、請求項19記載の組成物。 wherein said at least one chemotherapeutic agent is
20. The composition of claim 19, selected from the group consisting of doxorubicin, camptothecin, paclitaxel, docetaxel, 5-fluorouracil, gemcitabine, methotrexate, or combinations thereof.
赤血球細胞上の分子に特異的に結合する抗体試薬、赤血球細胞上の分子に特異的に結合するペプチド、細胞接着性ポリマー、細胞接着性高分子電解質、および赤血球細胞上の受容体に対するリガンド
からなる群より選択される、請求項27~28のいずれか一項記載の組成物。 wherein the cell adhesion molecule is
It consists of an antibody reagent that specifically binds to a molecule on red blood cells, a peptide that specifically binds to a molecule on red blood cells, a cell-adhesive polymer, a cell-adhesive polyelectrolyte, and a ligand for a receptor on red blood cells. 29. The composition according to any one of claims 27-28, selected from the group.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962858478P | 2019-06-07 | 2019-06-07 | |
US62/858,478 | 2019-06-07 | ||
PCT/US2020/036040 WO2020247576A1 (en) | 2019-06-07 | 2020-06-04 | Compositions and methods relating to erythrocytes with adhered particles |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022534796A JP2022534796A (en) | 2022-08-03 |
JPWO2020247576A5 true JPWO2020247576A5 (en) | 2023-05-09 |
Family
ID=73652929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021572295A Pending JP2022534796A (en) | 2019-06-07 | 2020-06-04 | Compositions and methods relating to red blood cells with adherent particles |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220323603A1 (en) |
EP (1) | EP3979994A4 (en) |
JP (1) | JP2022534796A (en) |
CN (1) | CN114222564A (en) |
AU (1) | AU2020287620A1 (en) |
CA (1) | CA3140681A1 (en) |
IL (1) | IL288743A (en) |
WO (1) | WO2020247576A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3223081A1 (en) | 2021-07-15 | 2023-01-19 | Samir Mitragotri | Compositions and methods relating to cells with adhered particles |
WO2023169528A1 (en) * | 2022-03-11 | 2023-09-14 | 西湖生物医药科技(上海)有限公司 | Engineered red blood cell targeting pd-1 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6998393B2 (en) * | 2000-06-23 | 2006-02-14 | Biopharm Solutions, Inc. | Aquespheres, their preparation and uses thereof |
AU2003300043A1 (en) * | 2002-10-10 | 2004-05-04 | Elizabeth Chambers | Carriers attached to blood cells |
DK1984009T3 (en) * | 2006-01-18 | 2013-01-28 | Qps Llc | Pharmaceutical compositions with improved stability |
US11400114B2 (en) * | 2016-03-15 | 2022-08-02 | Massachusetts Institute Of Technology | Synthetically functionalized living cells for targeted drug delivery |
-
2020
- 2020-06-04 US US17/616,760 patent/US20220323603A1/en active Pending
- 2020-06-04 EP EP20818165.1A patent/EP3979994A4/en active Pending
- 2020-06-04 CN CN202080056426.2A patent/CN114222564A/en active Pending
- 2020-06-04 AU AU2020287620A patent/AU2020287620A1/en active Pending
- 2020-06-04 WO PCT/US2020/036040 patent/WO2020247576A1/en unknown
- 2020-06-04 JP JP2021572295A patent/JP2022534796A/en active Pending
- 2020-06-04 CA CA3140681A patent/CA3140681A1/en active Pending
-
2021
- 2021-12-07 IL IL288743A patent/IL288743A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6731405B2 (en) | Cancer immunotherapy using viral particles | |
JP5704788B2 (en) | Combined immunogene therapy and chemotherapy for the treatment of cancer and hyperproliferative diseases | |
Bourquin et al. | Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists | |
Krosnick et al. | Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo | |
JP3976742B2 (en) | Immunostimulatory oligonucleotides that induce interferon alpha | |
KR960008009B1 (en) | Synergistic composition of interleukin and double strand rna | |
Amlie-Lefond et al. | Innate immunity for biodefense: a strategy whose time has come | |
Martell et al. | Host defense peptides as immunomodulators: The other side of the coin | |
Li et al. | The immunological mechanisms and therapeutic potential in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity | |
JPWO2020247576A5 (en) | ||
CN107708668A (en) | Nano-particle as therapeutic vaccine | |
JP2023164727A (en) | Compositions and methods for multi-adjuvant-only approach to immunoprophylaxis for preventing infections | |
Kokate | A systematic overview of cancer immunotherapy: an emerging therapy | |
Jung et al. | TLR Agonists Delivered by Plant Virus and Bacteriophage Nanoparticles for Cancer Immunotherapy | |
US20230287075A1 (en) | Dual cytokine fusion proteins comprising multi-subunit cytokines | |
Merigan | Interferon stimulated by double stranded RNA | |
KR100913860B1 (en) | Oligonucleotide compositions and their use to induce differentiation of cells | |
WO2021258008A1 (en) | Compositions and methods for treating and preventing viral infection | |
US20160186138A1 (en) | Natural Killer Cells and Methods for Enhancing Viability, Proliferation and Cytotoxicity of Same Following Cryopreservation | |
JP2004508290A (en) | Use of granular vectors in immunomodulation | |
Adachi et al. | Tumoricidal effect of human macrophage-colony-stimulating factor against human-ovarian-carcinoma-bearing athymic mice and its therapeutic effect when combined with cisplatin | |
WO2020228606A1 (en) | Dimeric cpg oligonucleotides for use in modulating immune responses | |
KANASUGI et al. | Optimal dose of enterococcal preparation (FK-23) supplemented perorally for stimulation of leukocyte reconstitution in dogs treated with cyclophosphamide | |
JOHNSON | Regulation of the immune system by nucleic acids and polynucleotides | |
CN117695242A (en) | Cyclic dinucleotide self-assembled nanoparticle and preparation and application thereof |